Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding a...( LYON France Oct. 8 /- Vical Incor...),Health

LYON, France, Oct. 8 /PRNewswire/ -- Vical Incorporated (Nasdaq: VICL) today is presenting expanded clinical data and new nonclinical data demonstrating that the company's Vaxfectin(R) adjuvant may be broadly applicable in DNA- and protein-based infectious disease vaccines and peptide-based cancer vaccines. Alain P. Rolland, Pharm.D., Ph.D., Vical's Senior Vice President of Product Development, will present the data today, Wednesday, October 8, at the World Vaccine Congress (Lyon, France - October 6-9).

Vaxfectin(R)-formulated Cancer Vaccines

In a mouse study, a Vaxfectin(R)-formulated vaccine containing a peptide from Tyrosinase-Related Protein 2 (TRP-2), an antigen commonly expressed by several types of tumors including glioma and melanoma, resulted in approximately a 100-fold increase in antigen-specific CD8+ T-cell responses compared with unformulated vaccine. CD8+ T-cells are deployed by the immune system to identify and destroy infected or cancerous cells.

Vaxfectin(R)-formulated Protein Vaccines

Vical has previously reported that data from studies in mice demonstrated the potential of the Vaxfectin(R) adjuvant to be used as a dose-sparing agent with protein-based commercial seasonal influenza vaccine and with protein-based H5N1 pandemic influenza vaccine currently stockpiled by the U.S. government. Vaxfectin(R)-formulated vaccine produced higher antibody responses than up to 10-fold higher doses of unformulated vaccine. Dose-sparing could be critical in extending limited vaccine supplies to protect the greatest number of people in the event of a pandemic influenza outbreak.

Data from additional studies in mice presented for the first time today demonstrated that Vaxfectin(R)-formulated seasonal in
'/>"/>